<span item_type="fundamental" item_id="6fa02a4d05699b7462007d465262492c" counter_id="ST/US/ANEB" env="prod"></span><span item_type="announcement" item_id="582437097635710849" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.05, beating the estimate of USD -0.12.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -2.352 M.</p><p></p><h3>Operating Expenses</h3><p>Operating expenses for the first quarter of fiscal 2026 were $2.3 million, compared to $2.4 million in the same period of fiscal 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm"></span></p><h3>Net Loss</h3><p>Net loss for the first quarter of fiscal 2026 was $2.2 million, or - $0.05 per share, compared to a net loss of $2.2 million, or - $0.08 per share, in the first quarter of fiscal 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm"></span></p><h3>Cash and Cash Equivalents</h3><p>Cash and cash equivalents were $10.4 million as of September 30, 2025. The company also has access to an additional $3.0 million in cash through a Loan Agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm"></span></p><h3>Total Assets and Liabilities</h3><p>Total assets as of September 30, 2025, were $10.7 million, with total liabilities amounting to $963,821.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Anebulo Pharmaceuticals anticipates selonabant will rapidly reverse key symptoms of acute cannabis-induced toxicity. The company is prioritizing the advancement of a selonabant IV formulation for pediatric patients, which it believes offers a faster timeline to approval compared to the adult oral product.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm"></span></p>

Anebulo Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0